Ribozyme targeting of HIV-1 LTR

Area of Science:

• Molecular Biology
• Virology
• RNA Therapeutics

Background:

• The 5'-TAR (Trans-Activation Response) region of Human Immunodeficiency Virus type 1 (HIV-1) mRNA is a highly conserved sequence essential for viral replication.
• Targeting conserved viral elements is a key strategy for developing broad-spectrum antiviral therapies.

Purpose of the Study:

• To investigate the potential of using hammerhead ribozymes to target the conserved 5'-TAR RNA element of HIV-1 mRNA in vivo.
• To assess the efficacy and mechanism of ribozyme-mediated inhibition of HIV-1 gene expression.

Main Methods:

• Utilized a transient assay system employing the CAT (chloramphenicol acetyltransferase) reporter gene linked to the HIV-1 Long Terminal Repeat (LTR).
• Designed and tested a hammerhead ribozyme specifically targeting the first GUC sequence within the HIV-1 TAR element.
• Evaluated sequence-specific inhibition and distinguished between cleavage activity and antisense effects.

Main Results:

• A hammerhead ribozyme targeting the HIV-1 TAR element demonstrated efficient inhibition of CAT protein expression in transient assays.
• The observed inhibition was sequence-specific, indicating a targeted molecular interaction.
• Evidence suggested that the inhibition mechanism primarily involves RNA cleavage rather than a simple antisense effect.
• Remarkably, a ribozyme inactive in vitro retained its inhibitory activity within a cellular environment, highlighting the potential of intracellular targeting.

Conclusions:

• Targeting the conserved HIV-1 TAR RNA element with hammerhead ribozymes is a feasible and effective strategy for inhibiting viral gene expression.
• Hammerhead ribozymes, even those inactive in vitro, can function effectively within a cellular context to disrupt viral processes.
• This research supports the development of hammerhead ribozyme-based therapeutics as a viable approach for anti-HIV therapy.